Clinical Trials
7 trialsNCT04585477 2026-02-10
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
Phase 2 Recruiting
NCT07129772 2025-09-04
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
Phase 2 Not yet recruiting
NCT04767009 2025-04-30
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Fudan University
Phase 2 Unknown
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT01094548 2016-02-22
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00157209 2015-11-18
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed